^
Association details:
| Biomarker: | HMOX1 expression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib
Excerpt:
...for both sorafenib- or sunitinib-treated patients, the CBR of low HO-1 expression was significantly higher than the CBR of high HO-1 expression. The results showed that the HO-1 expression level is significantly associated with sensitivity to sorafenib and sunitinib.
DOI:
10.2147/OTT.S86222
